Exhibit 10.34
-------------
AMENDMENT NO. 4
---------------
TO
--
KIRIN-AMGEN, INC./AMGEN
-----------------------
G-CSF EUROPEAN LICENSE AGREEMENT
--------------------------------
THIS AMENDMENT NO. 4 ("Amendment No. 4") TO THAT CERTAIN
KIRIN-AMGEN, INC./AMGEN G-CSF EUROPEAN LICENSE AGREEMENT ("License
Agreement"), is made and entered into this 29/TH/ day of December, 1989, by
and between AMGEN INC., a Delaware corporation ("Amgen") and KIRIN-AMGEN,
INC., a California corporation ("Corporation").
R E C I T A L S
- - - - - - - -
A. Amgen and Corporation have previously executed that
certain License Agreement regarding G-CSF and Amendment Nos. 1, 2 and 3.
B. The parties desire to incorporate certain changes into
the License Agreement pursuant to this Amendment No. 4.
NOW, THEREFORE, it is agreed as follows:
1. Article II, Section 2.03(d) and (e) at page 5 of the License
Agreement are hereby deleted and the following substituted in lieu thereof:
"(d) $3,000,000 (U.S.) -- Filing of a Product Licensing
Application in the United States."
2. Except to the extent as provided herein, the provisions of
the License Agreement, as amended, are hereby ratified and confirmed in all
respects.
IN WITNESS WHEREOF, the undersigned have caused this
Amendment No. 4 to be executed as of the first day written above.
AMGEN INC., a Delaware
corporation
By /s/ Xxxxxx X. Xxxxxx
------------------------------
Xxxxxx X. Xxxxxx, Chief
Executive Officer
"Amgen"
KIRIN-AMGEN, INC.,
a California corporation
By /s/ X. Xxxxxxxx
------------------------------
Yashushi Yamamoto, Chairman
"Corporation"
